Cost-Utility Analysis of Mycophenolate Mofetil versus Azathioprine Based Regimens for Maintenance Therapy of Proliferative Lupus Nephritis

International Journal of Nephrology

Volumn 2015, Issue , 2015, Pages

  Nee, Robert ^a   Rivera, Ian ^a   Little, Dustin J ^a   Yuan, Christina M ^a   Abbott, Kevin C ^a  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84947460026     PISSN: 2090214X     EISSN: 20902158     Source Type: Journal    
DOI: 10.1155/2015/917567     Document Type: Article

References (40)

1. K. A. Slawsky, A. W. Fernandes, L. Fusfeld, S. Manzi, and T. F. Goss, "A structured literature review of the direct costs of adult systemic lupus erythematosus in the US," Arthritis Care & Research, vol. 63, no. 9, pp. 1224-1232, 2011.
2. G. Carls, T. Li, P. Panopalis et al., "Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis," Journal of Occupational and Environmental Medicine, vol. 51, no. 1, pp. 66-79, 2009.
3. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group, "KDIGO clinical practice guideline for glomerulonephritis," Kidney International Supplements, vol. 2, no. 2, pp. 139-274, 2012.
4. B. H. Hahn, M. A. McMahon, A. Wilkinson et al., "American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis," Arthritis Care and Research, vol. 64, no. 6, pp. 797-808, 2012.
5. F. A. Houssiau, D. D'Cruz, S. Sangle et al., "Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial," Annals of the Rheumatic Diseases, vol. 69, no. 12, pp. 2083-2089, 2010.
6. M. A. Dooley, D. Jayne, E. M. Ginzler et al., "Mycophenolate versus azathioprine asmaintenance therapy for lupus nephritis," The New England Journal ofMedicine, vol. 365, no. 20, pp. 1886-1895, 2011.
7. A. M. Gray, P. M. Clarke, J. L. Wolstenholme, and S. Wordsworth, Applied Methods of Cost-Effectiveness Analysis in Health Care,OxfordUniversity Press,New York,NY,USA, 2011.
8. D. Husereau, M. Drummond, S. Petrou et al., "Consolidated health economic evaluation reporting standards (CHEERS)-explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force," Value in Health, vol. 16, no. 2, pp. 231-250, 2013.
9. B. Sprangers, M. Monahan, and G. B. Appel, "Diagnosis and treatment of lupus nephritis flares-an update," Nature Reviews Nephrology, vol. 8, no. 12, pp. 709-717, 2012.
10. R. J. Falk, P. H. Schur, andG. B. Appel, "Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis," UpTo-Date, May 2013, http://www.uptodate.com/.
11. Bureau of Labor Statistics, "Consumer Price Index," December 2013, http://www.bls.gov/cpi/home.htm.
12. Red Book Online, June 2013, http://www.redbook.com/redbook/online/.
13. L. Henderson, P. Masson, J. C. Craig et al., "Treatment for lupus nephritis," Cochrane Database of Systematic Reviews, vol. 12, Article ID CD002922, 2012.
14. K. H. Costenbader, A. Desai, G. S. Alarcón et al., "Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006," Arthritis & Rheumatism, vol. 63, no. 6, pp. 1681-1688, 2011.
15. F. A. Sonnenberg and J. R. Beck, "Markov models in medical decision making: a practical guide," Medical Decision Making, vol. 13, no. 4, pp. 322-338, 1993.
16. Centers for Medicare & Medicaid Services, December 2013, http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates.html.
17. A.E. Clarke, P. Panopalis,M. Petri et al., "SLEpatientswithrenal damage incur higher health care costs," Rheumatology, vol. 47, no. 3, pp. 329-333, 2008.
18. A. E. Clarke, M. Petri, S. Manzi et al., "The systemic lupus erythematosus tri-nation study: absence of a link between health resource use and health outcome," Rheumatology, vol. 43, no. 8, pp. 1016-1024, 2004.
19. P. Panopalis, M. Petri, S. Manzi et al., "The systemic lupus erythematosus tri-nation study: cumulative indirect costs," Arthritis Care and Research, vol. 57, no. 1, pp. 64-70, 2007.
20. US Renal Data System, USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md, USA, 2012.
21. Healthcare Cost and Utilization Project and Agency forHealthcare Research and Quality, 2013, http://hcupnet.ahrq.gov/HCUPnet.jsp?Id=5452BD185046B6A8&Form=DispTab&JS= Y&Action=%3E%3ENext%3E%3E&GoTo=MAINSEL.
22. Y. S. Liem, J. L. Bosch, and M. G. M. Hunink, "Preferencebased quality of life of patients on renal replacement therapy: a systematic review andmeta-analysis," Value in Health, vol. 11, no. 4, pp. 733-741, 2008.
23. C. Grootscholten, F. J. Snoek, M. Bijl et al., "Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/methylprednisolone in a randomized controlled trial," Journal of Rheumatology, vol. 34, no. 8, pp. 1699-1707, 2007.
24. K. C. Tse, C. S. O. Tang, W. I. Lio, M. F. Lam, and T. M. Chan, "Quality of life comparison between corticosteroid-andmycofenolate mofetil and corticosteroid-and-oral cyclophosphamide in the treatment of severe lupus nephritis," Lupus, vol. 15, no. 6, pp. 371-379, 2006.
25. Tufts' Cost-Effectiveness Analysis Registry, December 2013, https://research.tufts-nemc.org/cear4/Home.aspx.
26. M. F. Drummond, M. J. Sculpher, G.W. Torrance, B. J. O'Brien, and G. L. Stoddart, Methods for the Economic Evaluation of Health Care Programmes, Oxford University Press, New York, NY, USA, 3rd edition, 2005.
27. S. Bernatsky, J.-F. Boivin, L. Joseph et al., "Mortality in systemic lupus erythematosus," Arthritis & Rheumatism, vol. 54, no. 8, pp. 2550-2557, 2006.
28. E. Arias, "United States life tables, 2007," National Vital Statistics Reports, vol. 59, pp. 1-60, 2011.
29. S. Sule, B. Fivush, A. Neu, and S. Furth, "Increased risk of death in pediatric and adult patients with ESRD secondary to lupus," Pediatric Nephrology, vol. 26, no. 1, pp. 93-98, 2011.
30. R. S. Braithwaite, D. O. Meltzer, J. T. King Jr., D. Leslie, and M. S. Roberts, "What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?" Medical Care, vol. 46, no. 4, pp. 349-356, 2008.
31. M. C. Weinstein, J. E. Siegel,M. R. Gold, M. S. Kamlet, and L. B. Russell, "Recommendations of the panel on cost-effectiveness in health and medicine," Journal of the American Medical Association, vol. 276, no. 15, pp. 1253-1258, 1996.
32. B. Groot Koerkamp, M. C. Weinstein, T. Stijnen, M. H. Heijenbrok-Kal, and M. G. M. Hunink, "Uncertainty and patient heterogeneity in medical decision models," Medical Decision Making, vol. 30, no. 2, pp. 194-205, 2010.
33. F. A. Houssiau, C. Vasconcelos, D. D'Cruz et al., "The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide," Annals of the Rheumatic Diseases, vol. 69, no. 1, pp. 61-64, 2010.
34. C. C. Mok, R. C. L. Kwok, and P. S. F. Yip, "Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus," Arthritis and Rheumatism, vol. 65, no. 8, pp. 2154-2160, 2013.
35. O. Lenz, A. A. Waheed, A. Baig, A. Pop, and G. Contreras, "Lupus nephritis: maintenance therapy for lupus nephritis-do we now have a plan?" Clinical Journal of the American Society of Nephrology, vol. 8, no. 1, pp. 162-171, 2013.
36. E. C. F. Wilson, D. R. W. Jayne, E. Dellow, and R. J. Fordham, "The cost-effectiveness of mycophenolate mofetil as firstline therapy in active lupus nephritis," Rheumatology, vol. 46, no. 7, pp. 1096-1101, 2007.
37. A. Mohara, R. P. Velasco, N. Praditsitthikorn, Y. Avihingsanon, and Y. Teerawattananon, "A cost-utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand," Rheumatology, vol. 53, no. 1, Article ID ket304, pp. 138-144, 2014.
38. NICE guide to the methods of technology appraisal 2013, 2014, http://www.nice.org.uk/article/PMG9/chapter/5-The-referencecase.
39. D.M. Eddy,W. Hollingworth, J. J. Caro, J. Tsevat,K.M. McDonald, and J. B. Wong, "Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7," Medical Decision Making, vol. 32, no. 5, pp. 733-743, 2012.
40. A. D. Moore, A. E. Clarke, D. S. Danoff et al., "Can health utility measures be used in lupus research? A comparative validation and reliability study of 4 utility indices," Journal of Rheumatology, vol. 26, no. 6, pp. 1285-1290, 1999.